236 related articles for article (PubMed ID: 9810004)
21. In vitro study of farnesyltransferase inhibitor SCH 66336, in combination with chemotherapy and radiation, in non-small cell lung cancer cell lines.
Loprevite M; Favoni RE; De Cupis A; Scolaro T; Semino C; Mazzanti P; Ardizzoni A
Oncol Rep; 2004 Feb; 11(2):407-14. PubMed ID: 14719076
[TBL] [Abstract][Full Text] [Related]
22. Design and in vivo analysis of potent non-thiol inhibitors of farnesyl protein transferase.
Anthony NJ; Gomez RP; Schaber MD; Mosser SD; Hamilton KA; O'Neil TJ; Koblan KS; Graham SL; Hartman GD; Shah D; Rands E; Kohl NE; Gibbs JB; Oliff AI
J Med Chem; 1999 Aug; 42(17):3356-68. PubMed ID: 10464022
[TBL] [Abstract][Full Text] [Related]
23. Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells.
Smalley KS; Eisen TG
Int J Cancer; 2003 Jun; 105(2):165-75. PubMed ID: 12673674
[TBL] [Abstract][Full Text] [Related]
24. Inhibitors of farnesyl protein transferase. 4-Amido, 4-carbamoyl, and 4-carboxamido derivatives of 1-(8-chloro-6,11-dihydro-5H-benzo[5,6]- cyclohepta[1,2-b]pyridin-11-yl)piperazine and 1-(3-bromo-8-chloro-6,11- dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperazine.
Mallams AK; Rossman RR; Doll RJ; Girijavallabhan VM; Ganguly AK; Petrin J; Wang L; Patton R; Bishop WR; Carr DM; Kirschmeier P; Catino JJ; Bryant MS; Chen KJ; Korfmacher WA; Nardo C; Wang S; Nomeir AA; Lin CC; Li Z; Chen J; Lee S; Dell J; Lipari P; Liu M
J Med Chem; 1998 Mar; 41(6):877-93. PubMed ID: 9526562
[TBL] [Abstract][Full Text] [Related]
25. New class of azaheptapyridine FPT inhibitors as potential cancer therapy agents.
Zhu HY; Desai J; Cooper AB; Wang J; Rane DF; Kirschmeier P; Strickland C; Liu M; Nomeir AA; Girijavallabhan VM
Bioorg Med Chem Lett; 2014 Feb; 24(4):1228-31. PubMed ID: 24462667
[TBL] [Abstract][Full Text] [Related]
26. Trihalobenzocycloheptapyridine analogues of Sch 66336 as potent inhibitors of farnesyl protein transferase.
Njoroge FG; Vibulbhan B; Pinto P; Strickland CL; Bishop WR; Kirschmeir P; Girijavallabhan V; Ganguly AK
Bioorg Med Chem; 2003 Jan; 11(1):139-43. PubMed ID: 12467716
[TBL] [Abstract][Full Text] [Related]
27. [Anti tumor activity of farnesyl transferase inhibitor].
Yoshimatsu K; Nagasu T
Gan To Kagaku Ryoho; 1997 Jan; 24(2):145-55. PubMed ID: 9030225
[TBL] [Abstract][Full Text] [Related]
28. Induction of parathyroid hormone-related peptide by the Ras oncogene: role of Ras farnesylation inhibitors as potential therapeutic agents for hypercalcemia of malignancy.
Aklilu F; Park M; Goltzman D; Rabbani SA
Cancer Res; 1997 Oct; 57(20):4517-22. PubMed ID: 9377563
[TBL] [Abstract][Full Text] [Related]
29. Sch-66336 (sarasar) and other benzocycloheptapyridyl farnesyl protein transferase inhibitors: discovery, biology and clinical observations.
Taveras AG; Kirschmeier P; Baum CM
Curr Top Med Chem; 2003; 3(10):1103-14. PubMed ID: 12769711
[TBL] [Abstract][Full Text] [Related]
30. Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice.
Mangues R; Corral T; Kohl NE; Symmans WF; Lu S; Malumbres M; Gibbs JB; Oliff A; Pellicer A
Cancer Res; 1998 Mar; 58(6):1253-9. PubMed ID: 9515813
[TBL] [Abstract][Full Text] [Related]
31. Farnesyltransferase inhibitor SCH-66336 downregulates secretion of matrix proteinases and inhibits carcinoma cell migration.
Desrosiers RR; Cusson MH; Turcotte S; Béliveau R
Int J Cancer; 2005 May; 114(5):702-12. PubMed ID: 15609318
[TBL] [Abstract][Full Text] [Related]
32. Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer.
Kelland LR; Smith V; Valenti M; Patterson L; Clarke PA; Detre S; End D; Howes AJ; Dowsett M; Workman P; Johnston SR
Clin Cancer Res; 2001 Nov; 7(11):3544-50. PubMed ID: 11705875
[TBL] [Abstract][Full Text] [Related]
33. Identification of pharmacokinetically stable 3, 10-dibromo-8-chlorobenzocycloheptapyridine farnesyl protein transferase inhibitors with potent enzyme and cellular activities.
Taveras AG; Deskus J; Chao J; Vaccaro CJ; Njoroge FG; Vibulbhan B; Pinto P; Remiszewski S; del Rosario J; Doll RJ; Alvarez C; Lalwani T; Mallams AK; Rossman RR; Afonso A; Girijavallabhan VM; Ganguly AK; Pramanik B; Heimark L; Bishop WR; Wang L; Kirschmeier P; James L; Carr D; Liu M
J Med Chem; 1999 Jul; 42(14):2651-61. PubMed ID: 10411485
[TBL] [Abstract][Full Text] [Related]
34. Combination therapy with the farnesyl protein transferase inhibitor SCH66336 and SCH58500 (p53 adenovirus) in preclinical cancer models.
Nielsen LL; Shi B; Hajian G; Yaremko B; Lipari P; Ferrari E; Gurnani M; Malkowski M; Chen J; Bishop WR; Liu M
Cancer Res; 1999 Dec; 59(23):5896-901. PubMed ID: 10606231
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of human farnesyltransferase, BIM-46228.
Prevost GP; Pradines A; Brezak MC; Lonchampt MO; Viossat I; Ader I; Toulas C; Kasprzyk P; Gordon T; Favre G; Morgan B
Int J Cancer; 2001 Mar; 91(5):718-22. PubMed ID: 11267986
[TBL] [Abstract][Full Text] [Related]
36. A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines.
Sepp-Lorenzino L; Ma Z; Rands E; Kohl NE; Gibbs JB; Oliff A; Rosen N
Cancer Res; 1995 Nov; 55(22):5302-9. PubMed ID: 7585592
[TBL] [Abstract][Full Text] [Related]
37. Development of highly potent inhibitors of Ras farnesyltransferase possessing cellular and in vivo activity.
Leftheris K; Kline T; Vite GD; Cho YH; Bhide RS; Patel DV; Patel MM; Schmidt RJ; Weller HN; Andahazy ML; Carboni JM; Gullo-Brown JL; Lee FY; Ricca C; Rose WC; Yan N; Barbacid M; Hunt JT; Meyers CA; Seizinger BR; Zahler R; Manne V
J Med Chem; 1996 Jan; 39(1):224-36. PubMed ID: 8568812
[TBL] [Abstract][Full Text] [Related]
38. Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor.
Rose WC; Lee FY; Fairchild CR; Lynch M; Monticello T; Kramer RA; Manne V
Cancer Res; 2001 Oct; 61(20):7507-17. PubMed ID: 11606387
[TBL] [Abstract][Full Text] [Related]
39. Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors.
Castaneda C; Meadows KL; Truax R; Morse MA; Kaufmann SH; Petros WP; Zhu Y; Statkevich P; Cutler DL; Hurwitz HI
Cancer Chemother Pharmacol; 2011 Feb; 67(2):455-63. PubMed ID: 20972873
[TBL] [Abstract][Full Text] [Related]
40. Growth inhibition of ras-dependent tumors in nude mice by a potent ras-dislodging antagonist.
Egozi Y; Weisz B; Gana-Weisz M; Ben-Baruch G; Kloog Y
Int J Cancer; 1999 Mar; 80(6):911-8. PubMed ID: 10074926
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
